SL
SPRY icon

Salomon & Ludwin’s ARS Pharmaceuticals SPRY Stock Holding History

Salomon & Ludwin’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,785
Closed -$28.5K – 817
2024
Q1 		$28.5K Hold
2,785
– – ﹤0.01% 434
2023
Q4 		$10.5K Hold
2,785
– – ﹤0.01% 485
2023
Q3 		$10.5K Buy
+2,785
New +$18.3K ﹤0.01% 484

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Salomon & Ludwin's SPRY Position: Q2 2024 in Review

Salomon & Ludwin sold out of ARS Pharmaceuticals (SPRY) in Q2 2024, closing a stake of 2,785 shares — an estimated $28.5K sold.

Salomon & Ludwin first reported a position in SPRY in Q3 2023 and held it in 3 quarters. The position peaked at $28.5K in Q1 2024. 115 funds tracked by Wall St. Rank hold SPRY as of Q2 2024.

  • Salomon & Ludwin reported no remaining ARS Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Salomon & Ludwin sold 2,785 ARS Pharmaceuticals shares in Q2 2024, an estimated $28.5K.
  • Salomon & Ludwin first reported a position in ARS Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Salomon & Ludwin's ARS Pharmaceuticals position peaked at $28.5K in Q1 2024.
  • 115 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2024.

Based on Salomon & Ludwin's 13F filing for Q2 2024, filed 25 Jul 2024.